Abstract
Introduction
Activation of the fibroblast growth factor receptors (FGFRs) is a common oncogenic mechanism, with activation of the FGFRs occurring in a subset of nearly all common cancers (1, 2) . Activating genetic events in carcinomas include receptor amplification, mutation, and generation of aberrant receptor fusions through translocation (1, 2) . There is limited understanding of how these diverse oncogenic events differ in their signalling to downstream pathways, and consequently whether the same or different therapeutic approaches may be required to treat cancers with different genetic events.
Amplification of FGFR1 is found in ~10% breast cancer and ~15% squamous lung cancers, with amplification of FGFR2 found in ~8% gastro-oesophageal cancer and ~2% breast cancer (1) . We conducted a translational clinical trial to assess whether cancers with amplification of FGFR1 or FGFR2 respond to the selective FGFR inhibitor AZD4547 (3).
Patients were screened for the presence of amplification using criteria defined for detection of HER2 amplification (4) . Through the clinical trial we identify that high-level copy number amplification is required for response to selective FGFR inhibition. Through analysis of functional genomic screens (5), we show that high level FGFR2 amplified cell lines have a distinct oncogene addiction phenotype, that is characterized by PI3 kinase and mTOR signalling becoming dependent on FGFR signalling. We investigate the factors that predispose to oncogene addiction phenotype, and the implications for response to inhibitors targeting amplified receptor tyrosine kinases.
Results

FGFR2 amplified cancers have a high response rate to AZD4547
We assessed the activity of the FGFR selective inhibitor AZD4547 in FGFR1 amplified breast cancer and FGFR2 amplified gastro-oesophageal cancer. We screened 341 patients with advanced cancer by fluorescent in situ hybridization (FISH) for the presence of gene amplification, identifying FGFR1 amplification in 18% advanced estrogen receptor positive breast cancer and FGFR2 amplification in 9.0% advanced gastro-oesophageal cancer. Eight patients with FGFR1 amplified breast cancer and nine with FGFR2 amplified gastrooesophageal cancer were treated with AZD4547 in a translational clinical trial ( Supplementary Fig. 1A ). One FGFR1 amplified (12.5% response rate) and three FGFR2 amplified (33% response rate) patients had confirmed responses to AZD4547 ( Fig. 1D , P=0.0002 Wilcoxon matched pairs-signed rank test), as a pharmacodynamic marker of interrupting FGF23 signalling by FGFR inhibition (6) . There was no correlation of response to change in phosphate level. Both a continuous and intermittent schedule of AZD4547 were used in the trial (methods). Of the responders, patient 21 and 207 were treated on the intermittent schedule, and patients 269 and patient 316 received continuous treatment.
High-level clonal FGFR2 amplification is a therapeutic target for selective FGFR inhibitors
We investigated the pathological basis of response in FGFR amplified cancers, the relatively high response rate of FGFR2 amplified gastric cancers compared to FGFR1 amplified breast cancer, with FDG-PET reductions only in FGFR2 amplified cancers. We assessed relative FGFR copy number by digital PCR in baseline tumour biopsies of patients treated in the clinical trial. For all patients with gastric cancer, the gastro-esophageal disease was biopsied by endoscopy. The response of the site biopsied was concordant with response with other sites of disease. Multiple different tumour sites were biopsied in patients with breast cancer.
In the one patient who responded, the biopsied site responded along with other non-biopsied sites.
Cancers with high copy number (high-level) FGFR amplification were more likely to respond to AZD4547 (P=0.0026 Mann-Whitney U Test, Fig. 2A) , with response only observed in cancers with high-level amplification in this trial. Within FGFR2 amplified cancers, high-level amplification was associated with a substantially higher expression of both FGFR2 mRNA and FGFR2 protein assessed by immunohistochemistry on baseline biopsies ( Fig. 2B and Supplementary Fig. 2A and 2B ). Truncated isoforms of FGFR2 have been shown to be potentially important for FGFR2 oncogenic transformation (7, 8) . Only cancers with highlevel FGFR2 amplification had expression of the truncated FGFR2-C3 isoform although at varying levels suggesting that the C3 isoform was not critical to established cancers ( Supplementary Fig. 2C ). However, expression of FGFR2-C3 may have potential as a biomarker for enrichment of patients likely to respond to FGFR inhibition.
We explored the role of clonality in response to AZD4547 in FGFR2 amplified cancers, using in situ heterogeneity mapping (online methods). Two responding patients had clonal homogeneously amplified tumours (>99% tumour cells FGFR2 amplified), the third patient having insufficient residual baseline tissue to make an assessment, whereas all nonresponding patients had tumours with sub-clonal heterogeneous amplification with the presence of non-amplified tumour cells (Fig. 2C) . In particular, heterogeneity in FGFR2 amplification was noted in patient 135 that had a high-level amplified tumour that did not respond to AZD4547. There was limited evidence of heterogeneity and the presence of nonamplified tumour cells in patient 99 that also did not respond. Both patient 135 and 99 had day 15 FDG-PET responses ( Supplementary Fig 1C) , suggesting that sub-clonality may explain the clinical pattern of FDG response that did not subsequently result in tumour shrinkage and clinical response. We compared paired gene expression between baseline and day 15 on-treatment biopsies with a custom Nanostring panel. In the heterogeneously amplified tumour from patient 135, high FGFR2 mRNA expression was lost at day 15 ( Fig.   2D ), whilst in the homogeneously amplified cancers high FGFR2 mRNA expression was maintained at day 15. Similarly, in patient 135 FGFR2 copy number was substantially reduced at day 15 ( Supplementary Fig. 2D ). These findings may reflect the inherent difficulty of sampling in a heterogeneous tumour, but equally could reflect clonal selection by AZD4547. In paired gene expression analysis, the one FGFR1 amplified cancer that responded to AZD4547 had upregulation of estrogen receptor target genes in the day 15 biopsy (Supplementary Table 1 ), suggesting that unregulated estrogen signalling may have limited sensitivity to the FGFR inhibitor in this tumour.
High-level FGFR2 amplification occurred in only 5% gastric cancers (7/135, arbitrarily defined as FISH ratio>5), a prevalence that may present a barrier to future drug development. We assessed whether screening for amplification in circulating free plasma DNA could identify high-level clonal amplified cancers (9) . FGFR2 copy number was elevated in plasma DNA of all three responding patients (Fig. 2E) , and also in patient 99 who had a response in day 15 FDG-PET ( Supplementary Fig. 1C ). However, FGFR2 copy number was not elevated in plasma DNA of patient 135 with the sub-clonal amplification, and not in low-level amplified cancers, suggesting that plasma assessment has potential to screen for high-level and clonal amplified cancers, to overcome the challenge posed by screening for amplifications on tumour biopsies.
High-level FGFR2 amplified cancer models are highly sensitive to FGFR inhibition
This data suggested that high-level clonal amplification, in particular for FGFR2 amplified cancers, may be required for response to selective FGFR inhibitors, and we investigated why high-level amplification may associate with distinct addiction to FGFR signalling. We Fig. 3A ). Furthermore, FGFR2 high level amplified cell lines were more sensitive to FGFR inhibitors AZD4547 and PD173074 in vitro than low-level FGFR1 amplified cell lines, both in terms of lower EC50 and increased maximal effect (Fig. 3C and D) . Similarly, FGFR2 amplified cell lines were more sensitive to PD173074 than FGFR2 mutant cell lines (P=0.0357 Mann-Whitney U Test, Supplementary   Fig. 3B ), and the level of CNV correlated with sensitivity to FGFR inhibition (R=0.8095, P=0.0218, Supplementary Fig 3C) . In addition, AZD4547 robustly increased caspase 3/7 activation only in FGFR2 amplified cell lines (Fig. 3E ).
To validate these findings, we established patient derived xenografts (PDX) in nude mice from the baseline biopsies of two FGFR2 clonally amplified patients who responded to AZD4547 in the clinic (Fig. 1) . To validate the models we performed whole exome sequencing was on the patient's archival diagnostic tumour biopsies, baseline tumour biopsies, germline, and on the established PDX models. There was high agreement in somatic mutations between the PDX models and the patient's baseline tumour suggesting an absence of substantial genetic drift and that the models were an accurate representation of the baseline tumour biopsy (FG42/pt316 R=0.86, FG51/pt269 R=0.85, Supplementary Fig   3D) . Both PDX models, FG51 (pt269) and FG42 (pt316), were highly sensitive to AZD4547 in vivo, in FG51 median 70% tumour shrinkage and 2/5 complete responses, and in FG42 median 74% tumour shrinkage and 0/5 complete responses (Fig. 3F ). AZD4547 induced an apoptotic response as assessed by cleaved caspase 3 on PDX tumour lysates (Fig. 3G) . We set out to determine how PI3 kinase signalling becomes FGFR dependent in highly amplified cell lines. FGFRs signal to PI3 kinase in a canonical fashion through binding of the FGFR specific adapter protein FRS2 to GRB2 and GAB1 (12) . Silencing GRB2 modestly increased AKT phosphorylation in the SUM52 FGFR2 amplified cell line, and silencing FRS2 resulted in only a minor reduction of AKT phosphorylation ( Supplementary Fig. 5A -B). In addition the PI3 kinase regulatory subunit p85 (PIK3R1) did not appear to associate with FGFR2 as assayed by immunoprecipitation (Fig. 5A ), suggesting that FGFR2 signalling controlled PI3 kinase signalling through a non-canonical mechanism.
To explore how FGFR2 activated PI3 kinase, we assessed the phosphorylation of 49 receptor tyrosine kinases (RTK) in response to FGFR inhibition, noting reduced tyrosine phosphorylation of all receptor tyrosine kinases assayed in SUM52 ( Fig. 5E ).
The interaction between ERBB3 and p85 PI3K assayed by immunoprecipitation was inhibited by PD173074 (Fig. 5D) , and silencing of ERBB3 with multiple different siRNA partially reduced AKT phosphorylation in SUM52 and in SNU16 (Fig. 5E ). ERBB3 was not observed to interact with FGFR2, suggesting that FGFR2 may not phosphorylate ERBB3 directly (Fig. 5D) . Among a panel of cell lines, SNU16 were observed to have high expression of IGF1R ( Supplementary Fig. 5F ). In contrast to ERBB3, IGF1R phosphorylation was not decreased by PD173074 in SNU16 (Fig. 5B and 5F ), whilst inhibition of IGF1R with AEW541 also blocked AKT phosphorylation (Fig. 5G ) at concentrations that had no effect on FGFR2 auto-phosphorylation ( Supplementary Fig. 5G ). Similarly, levels of AKT phosphorylation were decreased by knockdown of IGF1R using siRNA (Supplementary Fig   5H) . Therefore, both FGFR2 and IGF1R signalling were necessary for signalling to PI3K-AKT in SNU16. Activation of PI3 kinase catalytic activity requires binding of GTP bound RAS to p110, or GTP bound CDC42/RAC1 to p110 (13) , and release from inhibitory effects of the p85 regulatory subunit (14) . Inhibition of FGFR signalling with PD173074, not IGF1R signalling with AEW541, reduced RAS activation in SNU16 (Fig. 5H) . Conversely, p85 PI3K that did not associate with FGFR2 (Fig. 5A ), bound to IRS1 in an IGF1R kinase dependent fashion (Fig. 5I) . Therefore PI3 kinase pathway signalling is activated through the combined effects of FGFR2 dependent activation of RAS, and p85 binding to ERBB3 and IGF1R/IRS1. FGFR2 signalling trans-phosphorylates ERBB3 to act as a scaffold to bind p85, with IGF1R signalling promoting IRS1 binding to p85, to thereby activate PI3 kinase signalling.
Discussion
The diversity of mechanisms through which FGFR signalling are activated in cancer present a clinical translational challenge, how similar or dissimilar are the different mechanisms of activating FGFR signalling? With a translational clinical trial we identify that cancers with high-level FGFR2 amplification form a distinct group characterized by a strong oncogene addiction phenotype and high sensitivity to AZD4547. High-level amplification initiates distinct signalling characterized by transactivation of alternative receptor tyrosine kinases to bring PI3 kinase and mTOR signalling under control of FGFR2.
Our study has implications for targeting amplified receptor tyrosine kinases (RTKs). The archetypal model for targeting amplified RTKs is that of HER2 amplification in breast cancer (15) , where the level of HER2 amplification does not affect sensitivity to the HER2 targeting antibody trastuzumab (16) . Our data suggests that HER2 amplification in breast cancer may be a limited model for targeting other amplified RTKs, and that criteria developed to identify cancers sensitive to HER2 targeting (a HER2 to centromere copy number ratio of >=2, and/or absolute HER2 copy number >=6) may not necessarily translate to other RTKs.
HER2 has unique biology amongst RTKs, lacking an activating ligand and with inherent potential for constitutive activation when over-expressed, and a very tight relationship between the presence of amplification of any copy number level and overexpression of HER2 (17) . In contrast, high-level FGFR copy number amplification associates with sensitivity to FGFR inhibition, with high-level amplification resulting in high expression of FGFR2 initiates a distinct oncogene addiction phenotype. In addition, low-level FGFR1/2 amplification does not strongly associate with FGFR over-expression (4) . Our data strongly suggests that clinical trials targeting FGFR, and potentially other RTKs, should consider higher thresholds for amplification. We also demonstrate the importance of assessing amplification clonality in predicting durable responses to therapy, the potential to assess the degree of heterogeneity using automated in situ heterogeneity mapping of FISH, and that it may be possible to identify patients with highly FGFR2 amplified gastric cancers by analysis of FGFR2 copy number in cell free plasma DNA, providing a potential simple strategy to screen patients for rare amplifications. Supplementary Fig.4 ), identifying a potential combination strategy for FGFR1 amplified cancers that do not exhibit a strong oncogene addiction phenotype that can be investigated in future research.
In this study we identify the importance of high-level clonal amplification in predicting response to FGFR selective inhibitors. High-level amplifications are of relatively low prevalence and we show that high-level clonal FGFR2 amplification can be detected through ctDNA screening, opening up a screening strategy to facilitate future development of drugs targeting amplified receptor tyrosine kinases.
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Methods
Clinical Trial Design
The FGFR trial (EudraCT No.:2011-003718-18) is a phase II, open label, non-randomised study of AZD4547 in patients with previously treated advanced FGFR amplified cancer.
Written informed consent was obtained from all patients. The study was carried out in accordance with the Declaration of Helsinki and approved by local institutional review boards. The study originally consisted of three independent tumour cohorts (FGFR1 amplified breast and squamous NSCLC and FGFR2 amplified gastroesophageal cancer), however due to poor accrual the lung cohort was closed to further recruitment. FGFR amplification testing was performed centrally on archival tissue and an FGFR ratio of ≥2.0 (FGFR1:CEP8 and FGFR2:CEP10) was required for study entry. Prior to treatment patients underwent a biopsy and PET-CT, repeated on study between day 10-14. Treatment consisted of AZD4547 80mg twice daily (initially on an intermittent schedule of two weeks on, one week off which was subsequently amended to continuous dosing). Primary endpoint was confirmed overall response rate. The study followed a Simon 2 stage, optimal design.
One or more responses were required in the initial 9 patients in each cohort, to recruit a total of 17 patients. Three of more patients were required to conclude that cohort had sufficient efficacy for further study. 
Cell lines and materials
Purification of DNA and RNA
DNA and RNA was extracted from fresh frozen tumour samples using AllPrep™ micro DNA/RNA extraction kit (QIAgen 80284) and from FFPE tumour samples using AllPrep™ DNA/RNA FFPE extraction kit (QIAgen 80234). In both cases a section was stained with haematoxylin and eosin and tumour marked out by a pathologist. Sections were cut and stained with nuclear fast red and tumour macrodissected prior to nucleic acid extraction using the appropriate kit. Plasma DNA was extracted from 2ml of plasma using QIAamp® Circulating Nucleic Acid kit (QIAGEN 55114) according to the manufacturer's guidelines.
Purified RNA was quantified using the Qubit® RNA HS Assay kit (Life Technologies, Q32855). Purified DNA was quantified using the Qubit® dsDNA HS Assay kit (Life Technologies, Q32854). Plasma DNA was quantified by ddPCR using the RPPH1 CNV reference assay to calculate copies/well and multiplying by the c-value (3.3pg), an estimate of the mass of a single haploid human genome.
Droplet digital PCR
Digital PCR was performed on a QX100 droplet PCR system (Bio-Rad). PCR reactions were prepared as previously described (9, 21) . Briefly, emulsified PCR reactions were run on a 96 well plate on a G-Storm GS4 thermal cycler incubating the plates at 95C for 10 min followed by 40 cycles of 95C for 15 sec, 60C for 60 sec, followed by 10 min incubation at 98 C.
Plates were read on a Bio-Rad QX100 droplet reader using QuantaSoft v1.6.6.0320 software. Copy number variation and gene expression for target genes were calculated as a ratio with multiplexed reference genes (Supplementary Table 3 ). Copy number variation assays were performed using 1-3ng genomic DNA, aiming to obtain a 300-600 reference droplets.
For gene expression assays, cDNA was prepared using SuperScript® III First Strand kit (Life Technologies, 18080-051), according to the manufacturer's guidelines using 50-200ng total RNA primed with random hexamers. ddPCR gene expression reactions (Supplementary   Table 3 ) were typically set up with 1-5ng RNA equivalent of cDNA. Target expression was normalized using βActin and GAPDH references assays.
In situ heterogeneity mapping
Briefly, fluorescent sections were scanned into the MIRAX (Pannoramic) scanner at high magnification in the x, y and z planes and analysed using custom HALO software. 
Nanostring
Probe sequences were custom designed and manufactured by Nanostring. Multiple probes were included against key genes including FGFR2. Probe specificity was confirmed using BLAT and Arrayviewer (Browser and Land software). The codeset was validated with cells lines and clinical tissue known to overexpress FGFR2. In addition to genes of interest the Codeset included a number of housekeeping genes to correct for RNA input amount and/or quality. A positive control (Universal Human Reference RNA (UHR), Stratagene, catalog #75000-41) was run routinely to ensure consistency between runs. Input total RNA amount was 100ng or 5ul neat RNA for more dilute/poor quality samples (based on internal QC control criteria).
Protocol was followed according to standard nCounter instructions. GEN2 Prep Station incubation time was set at the higher sensitivity setting (3hrs) and 280 Fields of View (FOV) were routinely captured unless otherwise noted.
Data was normalized through an internally developed Pipeline Pilot Tool (publicly available for use on the Comprehensive R Archive Network, CRAN). In brief, data were log2 transformed after being normalized in two steps: raw Nanostring counts were first background adjusted with a Truncated Poisson correction using negative control spikes followed by a technical normalization using positive control spikes. Data was then corrected for input amount variation through a Sigmoid shrunken slope normalization step using the mean expression of housekeeping genes. A transcript was designated as not detected if the raw count was below the average of the internal negative control raw counts plus 2 standard deviations.
siRNA screen
Screening in 384 well plates with a Dharmacon siGENOME SMART pools library targeting all known protein kinases and phosphatases as described previously (5) . To assess the effect of siRNA on growth/survival, the effect of siRNA in the vehicle plates was expressed as a Z score, with the standard deviation estimated from the median absolute deviation (MAD). To assess the effect of siRNA on sensitivity to PD173074 the log2 ratio between growth in PD173074 plates and vehicle plates was assessed and expressed as a Z score.
Western Blotting
Cell lines were grown on 35mm plates, treated as indicated, and lysed in NP40 lysis buffer, (1% v/v NP40, 10mM Tris.Cl pH8, 150mM NaCl, 1mM EDTA, 1mM DTT) supplemented with phosphatase (5mM Na4P2O7, 50mM NaF and 1mM NaVO4) and protease inhibitor cocktail (Roche, 11697498001). Cells were reverse transfected with siRNA 72 hours prior to lysis.
Western blots were carried out with precast TA or Bis-Tris gels (Life Technologies).
In vitro cell line assessment
Clonogenic assays were conducted in 6 well plates, with 1000 cells seeded per well, and 24 hours later cells exposed to vehicle, or the indicated treatments followed by growth in media for 2 weeks to allow colony growth. Colonies were fixed, stained with sulforhodamine B and counted. For PTEN siRNA clonogenics cells were treated for 1 week with PD173074 before wash out. For short-term survival assays, cells were exposed to indicated drugs with survival assessed after 72 hours exposure with Cell Titre-Glo cell viability assay (Promega, Madison, WI). To assess the effect of siRNA on drug sensitivity cells were reverse transfected at final siRNA concentration 20nM, at 48 hours post transfection plates were exposed to compound with survival was assessed after 72 hours exposure. To assess synergy cell lines were plated in 384 well plates, and the following day exposed to fixed-ratio combinations of indicated drugs for 72 hours, with combination index assessed according to Chou and Talalay (22) using Calcusyn v2.1 (BIOSOFT, UK).
Whole Exome Sequencing
Genomic DNA (30-200ng) was fragmented to 200bp using a Covaris E Series and the resultant libraries were subjected to DNA Capture using SureSelect XT Human All Exon v4 kit (Agilent) following manufacturer's instructions. Final libraries were quantified using qPCR and clustered at a molarity of 14.5pM, sequencing was performed on an Illuimna HiSeq 2000 using 2x75 cycles of version 3 SBS chemistry. Reads were aligned to the human reference genome (GRCh37) using BWA (v0.7.5a) (23) . PCR duplicates were filtered out from the subsequent analysis using Picard-tools (v1.94) and variants were called using the GATK pipeline (v2.3.9) best practices (24) . Somatic changes between germline, cancer samples and the PDX samples were investigated using MuTect (v1.1.4) (25) and filtered for on-target regions using bedTools (v2.17.0) Comparisons between allele frequencies of somatic mutations in the cancer and PDX samples were investigated using R (3.1.2). All sequencing data has been deposited in the NCBI Sequence Read Archive under accession SRP072158.
Apoptosis assessment
To assess apoptosis activated Caspase 3/7 activity was assessed using the Caspase-Glo® 3/7 Assay according to manufacturer's instructions (Promega, G8090) and adjusted for cell number as assessed by Cell Titre-Glo.
Phosphorylated RTK arrays
Cells and PDX were treated as indicated, lysates prepared using Lysis Buffer 17 and analysed using Human Phospho-RTK arrays (R&D Systems, ARY001B) according to the manufacturer's guidelines.
Immunoprecipitation
Cells were treated as indicated and lysates prepared using NP40 lysis buffer (without DTT).
The antibodies used for immunoprecipitation (IP) were p85 PI3K (ABS233, Millipore), ErbB3
(Thermo Scientific, MS-262-P1) and FGFR2 (Santa Cruz, SC122). Control IPs were performed with normal mouse (SC2025) and rabbit IgG (SC2027, both Santa Cruz Biotechnologies). Veriblot anti-rabbit IgG (ab131366) and anti-mouse IgG (ab131368, both Abcam) HRP conjugated secondary antibodies were used for IPs. 500-1000mg of total cellular protein were incubated with the antibodies and the protein complexes precipitated using Protein G coated Dynabeads (Life Technologies, 10001D).
Ras activation Assay
Ras activation was determined using the Ras activation assay kit (Millipore, according to the manufacturer's guidelines. Briefly, cell lysates were prepared using Mg 2+ Lysis/wash buffer (MLB). Samples were incubated with 10g Ras assay reagent (Raf1 Ras binding domain-agarose) and incubated for 45min at 4˚C. Agarose beads were pelleted by centrifugation and washed 3 times with MLB. Agarose beads were resuspended in NuPAGE LDS sample buffer (Life Technologies). Samples were subjected to western blotting as previously described and blots probed using anti-Ras antibody (clone RAS10, 05-516, Millipore).
Methyl 7-GTP pull down
Cells were lysed in NP40 lysis buffer. Pulldown mixes were prepared with 200μL containing 200μg total cellular protein and 40μL 7methyl GTP-sepharose 4B beads (GE Healthcare, 275025) to give a total volume of 240μL. Before use beads were washed twice with NP40 lysis buffer. Pulldown mixes were incubated overnight at 4˚C. Beads were washed twice with NP40 lysis buffer, bound complexes eluted in western sample loading buffer and resolved on precast Bis-Tris gels (Life Technologies).
AHA translation assay
Protein synthesis was assessed using the Click IT AHA-Alexa Fluor 488 Protein Synthesis 
Immunohistochemistry
Following deparafinisation and rehydration, antigen retrieval was, followed by blocking of endogenous peroxidise activity using H2O2 block (Dako Envision Flex kit, K8000).
For FGFR2 IHC, antigen retrieval was with pressure cooking in pH 9 retrieval buffer 
